Pages
- Terumo
- Edwards Lifesciences
- Client Portals
- CRI-The Clinical Research Institute
- Home
- Website Accessibility Statement
- Expertise
- Subject Matter Experts
- Therapeutic Expertise
- Wound Care
- Cardiovascular
- Dental
- Other Therapeutic Areas
- General Surgery
- Neurology
- IVD & Companion Diagnostics
- Ophthalmology
- Orthopedics
- Peripheral Vascular
- Anesthesia / Respiratory
- Diabetics
- Diagnostic Imaging
- Ear / Nose / Throat
- Gastroenterology
- Oncology
- OBSTETRICS & GYNECOLOGY (OB/GYN)
- Regenerative Medicine
- Services
- Preclinical Research
- Medical Device Regulatory & Quality
- Medical Writing Solutions
- Product Development Strategy
- Biological Safety
- Medical Device Testing
- NAMSA APEX PROGRAM
- Medical Device Reimbursement
- MedTech Market Research Consulting
- Sterilization Validation
- Clinical Research
- IVD
- Product Development Strategy
- APEX Program
- Medical Device Regulatory & Quality
- ÅKRN
- SUAZIO
- SUAZIO
- Sign Up
- Account
- Perfectus Biomed Group
- APS
- European Union’s General Data Protection Regulation Frequently Asked Questions – Vendors
- Clinlogix
- Medanex
- European Union’s General Data Protection Regulation Frequently Asked Questions – Clients
- NAMSA 360 Client Portal Tutorial
- Opportunities to Accelerate Clinical Research Through Outpatient Site Networks
- Lessons Learned: Notified Body Feedback Regarding Client Submissions
- Movement to Molecular Diagnostics for Infectious Disease
- The Critical Role of Toxicologists in Chemical Characterization
- NAMSA APEX PROGRAM Advantage
- Syntactx
- The Importance of Selecting the Right Partner
- Strategies for Selecting the Proper Investigational Sites for Pivotal Studies
- NAMSA’s Clinical Research Capabilities
- The Value of Market Insights
- Trends in MedTech Outsourcing
- Key Considerations for Chemical Characterization Programs
- Understanding Today’s MedTech Landscape for Start-Ups: Part 1
- Flexible Strategies for Outsourcing Clinical Research: Augmented and Full Sourcing Models
- Best Practices for Conducting Medical Device Antiviral and Microbial Testing
- Considerations for Selecting the Best-Fit MedTech Regulatory Partner
- Resources
- Checklists and Sample Submission Forms
- EU MDR & IVDR Planning Resources
- MedTech Podcast and Video Series
- RA QA Café Podcast
- Human Factors: Real Life Testing for Real Life Experiences
- Updates on the IVDR
- Risk Management, Clinical Evidence and Post-Market Reporting
- Effective Communication with Notified Bodies
- RAQA Café Live! – RAPS EU Convergence and Effective MDR-Compliant Periodic Safety Update Reports
- Talking Risk with Dr. Naveen Agarwal-Part 2
- Talking Risk with Dr. Naveen Agarwal-Part 1
- Compliance Pitfalls of In Vivo Studies—How to Learn from the Mistakes of Others
- The EU IVDR: What Do You Need To Know?
- Clinical Investigations: Collecting Proof That Your Device is Safe and Effective
- IVD Special – Software in a Medical Device (SiMD) vs. Software as a Medical Device (SaMD): Understanding Regulatory Differences and Expectations
- Software in a Medical Device (SIMD) vs. Software as a Medical Device (SaMD): Understanding Regulatory Differences and Expectations
- Refuse to Accept Policy and the Future of FDA Submissions
- Choosing the Right Consultant
- MedTech Matters Video Series
- BiocompCHATibility Podcast
- Navigating Biocompatibility in Early Feasibility Studies
- Exploring Equivalency in Biocompatibility
- Chemistry with the MFDS
- New FDA Biocompatibility Guidance – Let’s Discuss
- NAMSA Awarded ASCA Accreditation
- Welcome to the RA QA Café
- What Exactly is my Test Article?
- Biocompchatibility – Welcome
- CSI: Cracking the Case
- Extractions: The How and Why
- FDA Thoughts On Chemical Characterization
- Don’t Forget Packaging!
- Welcome to NAMSA: Lisa Olson
- Editor Chat: Biocompatibility and Performance of Medical Devices
- NAMSA Training Series: Live from Philadelphia
- NAMSA Training Series: Live from Frankfurt
- Discussion with Chemical Characterization “A-Lister” Ted Heise on the New ISO 10993-18
- Reusable Devices and the Challenges with Biocompatibility
- Answering Your Questions on ISO 10993-18:2020
- The QB1 of GLP
- Biological Equivalency: When is “same” the same?
- The Biological Evaluation Plan: A Manufacturer’s Perspective with Guest Dave Parente of Ecolab
- Biocomp and Beer
- Covid 19: Biocompatibility of Ventilators and Respiratory Devices
- Biocompatibility FAQ
- Listener MailBag – We Answer Your Questions
- FDA and ISO 10993-18:2020
- Why Biocompatibility Cares about Preclinical: NAMSA and APS Discuss
- When to Go with In Vitro: Your Irritation Questions Answered
- Oh No, Another Failed Cyto!
- Is your Biocompatibility Program Knocking your Submission Off Track?
- The Facts About In Vitro Irritation
- Intact Skin Contact Devices: To Test or Not to Test
- What in the World is the FDA’s Lab Accreditation Program – ASCA?
- ISO 10993-4: The Second Most Misunderstood Section of 10993
- Finding the Qualified Biocompatibility Unicorn
- Biocompatibility and the Pre-Submission Meeting – The Devil is in the Details
- A Start-up Biocompatibility Story – Prescient Surgical
- RA QA Café Podcast
- Blog
- Resource Library
- NAMSA Medical Device Test Navigators
- E-Learning
- Careers
- NAMSA’s Client Standard Terms and Conditions
- EU-U.S., UK Extension & Swiss-U.S. Data Privacy Framework
- Website Privacy Statement
- Website Terms of Use
- APEX Program Consultation
- NAMSA Purchasing Terms and Conditions
- Contact
- About
- Events
- Certifications and Accreditations
- Site Map